Article Text

other Versions

Download PDFPDF
Effects of strontium ranelate on spinal osteoarthritis progression
  1. Olivier Bruyere (olivier.bruyere{at}
  1. University of Liege, Belgium
    1. Danielle Delferriere
    1. University of Liege, Belgium
      1. Christian Roux
      1. Department of Rheumatology, Cochin Hospital, Paris, France
        1. John D Wark
        1. Department of Medicine and Bone & Mineral Service, Royal Melbourne Hospital, Parkville, Australia
          1. Tim Spector
          1. Department of Rheumatology, & Genetic Epidemiology, St Thomas Hospital, Kings Collegue, London, United Kingdom
            1. Jean-Pierre Devogelaer
            1. St-Luc University Hostpital, Université Catholique de Louvain, Brussels, Belgium
              1. Kim Brixen
              1. Department of Endocrinology, Odense University Hospital, Odense, Denmark
                1. Silvano Adami
                1. Department of Rheumatology Unit, Valeggio, Italy
                  1. Jacques Fechtenbaum
                  1. Department of Rheumatology, Cochin Hospital, Paris, France
                    1. Sami Kolta
                    1. Department of Rheumatology, Cochin Hospital, Paris, France
                      1. Jean-Yves Reginster
                      1. University of Liege, Belgium


                        Objective: The aim of the present study was to determine whether a 3-year treatment with strontium ranelate could delay the progression of spinal osteoarthritis (OA).

                        Methods: This study was a post-hoc analysis of pooled data from the Spinal Osteoporosis Therapeutic Intervention (SOTI) and TReatment Of Peripheral OSteoporosis (TROPOS) trials performed on 1105 osteoporotic women with concomitant radiological spinal OA at baseline and for whom lumbar x-rays were available at baseline and over the 3-year treatment period. The presence and severity of osteophytes, disc space narrowing, and sclerosis in the lumbar intervertebral spaces was graded according to the method of Lane et al, and an overall OA score was calculated for each intervertebral space. Back pain (measured on a 5-point Likert scale only in SOTI) and health-related quality of life (SF-36 questionnaire) were assessed at baseline and after 3 years. Patients who suffered an incident or progressive vertebral fracture during the study were excluded from the analysis.

                        Results: Strontium ranelate, compared with placebo, reduced by 42% the proportion of patients with worsening overall spinal OA score (RR, 0.58; 95% CI, 0.42-0.79; P=0.0005). Significantly more patients in the strontium ranelate group experienced an improvement in back pain after 3 years, compared with placebo (P=0.03), while no significant difference was observed in terms of health-related quality of life between these patients groups.

                        Conclusion: The results of this post-hoc analysis suggest that strontium ranelate could reduce radiographic spinal OA progression and back pain in osteoporotic women with prevalent spinal OA.

                        • SF-36
                        • back pain
                        • osteoarthritis
                        • spine
                        • strontium ranelate

                        Statistics from

                        Request Permissions

                        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.